Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

The roles of CD73 in cancer.

Tytuł :
The roles of CD73 in cancer.
Autorzy :
Gao ZW; Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xinsi Road, Xi'an, Shanxi 710038, China.
Dong K; Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xinsi Road, Xi'an, Shanxi 710038, China.
Zhang HZ; Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xinsi Road, Xi'an, Shanxi 710038, China.
Pokaż więcej
Źródło :
BioMed research international [Biomed Res Int] 2014; Vol. 2014, pp. 460654. Date of Electronic Publication: 2014 Jul 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
Język :
English
Imprint Name(s) :
Original Publication: New York, NY : Hindawi Pub. Co.
MeSH Terms :
5'-Nucleotidase/*genetics
Carcinogenesis/*genetics
Neoplasms/*metabolism
Neovascularization, Pathologic/*genetics
5'-Nucleotidase/biosynthesis ; 5'-Nucleotidase/metabolism ; Adenosine/metabolism ; Adenosine Monophosphate/metabolism ; Animals ; Cell Proliferation ; GPI-Linked Proteins/biosynthesis ; GPI-Linked Proteins/genetics ; GPI-Linked Proteins/metabolism ; Gene Expression Regulation, Neoplastic ; Humans ; Mice ; Neoplasms/classification ; Neoplasms/genetics
References :
Purinergic Signal. 2013 Dec;9(4):491-540. (PMID: 23797685)
Biochim Biophys Acta. 2011 Jul;1813(7):1263-8. (PMID: 20732359)
PLoS One. 2012;7(10):e47468. (PMID: 23094051)
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52. (PMID: 20080644)
J Immunol. 2005 Oct 1;175(7):4383-91. (PMID: 16177079)
Oncol Rep. 2007 Jun;17(6):1341-6. (PMID: 17487388)
J Gynecol Oncol. 2012 Oct;23(4):274-81. (PMID: 23094131)
J Immunol. 2011 Dec 1;187(11):6120-9. (PMID: 22039302)
IUBMB Life. 2012 Nov;64(11):911-20. (PMID: 23086814)
Pharmacol Ther. 2006 Nov;112(2):358-404. (PMID: 16784779)
Clin Exp Metastasis. 2007;24(6):439-48. (PMID: 17587186)
Cancer Sci. 2010 Dec;101(12):2561-9. (PMID: 20874842)
J Surg Oncol. 2012 Aug 1;106(2):130-7. (PMID: 22287455)
Mol Cell Biochem. 2008 Dec;319(1-2):61-8. (PMID: 18636315)
Blood. 2008 Sep 1;112(5):1822-31. (PMID: 18559975)
Mol Cell Biochem. 2004 Oct;265(1-2):195-201. (PMID: 15543949)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Cell Tissue Res. 2014 Feb;355(2):365-74. (PMID: 24310606)
Trends Immunol. 2012 May;33(5):231-7. (PMID: 22487321)
Blood. 2011 Dec 1;118(23):6141-52. (PMID: 21998208)
Clin Exp Metastasis. 2013 Jun;30(5):671-80. (PMID: 23508889)
Am J Transl Res. 2014 Jan 15;6(2):129-39. (PMID: 24489992)
Biochimie. 2013 Jun;95(6):1110-9. (PMID: 23507428)
Mol Cell Endocrinol. 2003 Jul 31;205(1-2):107-14. (PMID: 12890572)
Oncogene. 2010 Sep 30;29(39):5346-58. (PMID: 20661219)
Clin Cancer Res. 2013 Oct 15;19(20):5626-35. (PMID: 23983257)
Ann N Y Acad Sci. 2007 Sep;1110:641-8. (PMID: 17911479)
Urol Oncol. 2010 May-Jun;28(3):260-7. (PMID: 19372055)
Acta Pharmacol Sin. 2006 Aug;27(8):1085-92. (PMID: 16867263)
Oncoimmunology. 2013 Jan 1;2(1):e22448. (PMID: 23483072)
J Cancer Res Clin Oncol. 2008 Mar;134(3):365-72. (PMID: 17671792)
Cardiovasc Res. 2013 Jan 1;97(1):88-96. (PMID: 22977005)
Int J Cancer. 2014 Mar 15;134(6):1466-73. (PMID: 23982901)
Br J Cancer. 2012 Apr 10;106(8):1446-52. (PMID: 22454080)
Neurochem Int. 2012 Oct;61(5):681-8. (PMID: 22750273)
Oncol Rep. 2014 Feb;31(2):819-27. (PMID: 24297662)
Immunotherapy. 2012 Sep;4(9):861-5. (PMID: 23046227)
J Mol Med (Berl). 2013 Feb;91(2):165-72. (PMID: 23292173)
Mol Cell Biochem. 2006 Sep;289(1-2):65-72. (PMID: 16718378)
Oncoimmunology. 2012 Mar 1;1(2):217-218. (PMID: 22720247)
J Surg Oncol. 2012 Dec;106(7):918-9; author reply 920. (PMID: 22585744)
Biochim Biophys Acta. 2012 Oct;1823(10):1967-75. (PMID: 22967714)
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11091-6. (PMID: 23776241)
Pathol Oncol Res. 2013 Oct;19(4):811-4. (PMID: 23653114)
J Immunol. 2004 Feb 1;172(3):1646-53. (PMID: 14734746)
Oncoimmunology. 2012 Jan 1;1(1):67-70. (PMID: 22720214)
Cancer Biol Ther. 2007 Mar;6(3):426-31. (PMID: 17471030)
Leukemia. 2011 Aug;25(8):1374-6. (PMID: 21760591)
Purinergic Signal. 2013 Jun;9(2):145-65. (PMID: 23271562)
Cancer Res. 2011 Apr 15;71(8):2892-900. (PMID: 21292811)
Acta Biochim Pol. 2012;59(4):647-52. (PMID: 23162807)
World J Gastroenterol. 2013 Mar 28;19(12):1912-8. (PMID: 23569336)
Am J Cancer Res. 2014 Mar 01;4(2):172-81. (PMID: 24660106)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Cancer Res. 2010 Mar 15;70(6):2245-55. (PMID: 20179192)
Biochim Biophys Acta. 2008 May;1783(5):673-94. (PMID: 18302942)
Eur J Immunol. 2011 May;41(5):1231-41. (PMID: 21469131)
Int J Cancer. 1996 Nov 15;68(4):493-500. (PMID: 8945621)
J Biomed Biotechnol. 2012;2012:473712. (PMID: 23133312)
Cell Physiol Biochem. 2013;32(2):355-66. (PMID: 23988425)
Urol Oncol. 2013 Oct;31(7):1204-11. (PMID: 22137869)
Appl Immunohistochem Mol Morphol. 2012 Mar;20(2):103-7. (PMID: 22553809)
Curr Med Chem. 2011;18(34):5217-23. (PMID: 22087822)
Br J Cancer. 2012 Jun 26;107(1):75-83. (PMID: 22653144)
Microvasc Res. 2006 Jul-Sep;72(1-2):48-53. (PMID: 16828810)
Exp Cell Res. 2004 Jun 10;296(2):99-108. (PMID: 15149841)
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1141-4. (PMID: 22040959)
Eur J Immunol. 2007 Dec;37(12):3334-8. (PMID: 18034430)
Tumour Biol. 2013 Apr;34(2):1085-95. (PMID: 23345014)
Cancer Res. 2012 May 1;72(9):2190-6. (PMID: 22396496)
Biochem Biophys Res Commun. 2011 Jul 22;411(1):62-8. (PMID: 21708136)
J Immunol. 2000 Nov 1;165(9):5262-8. (PMID: 11046060)
J Cell Physiol. 2013 Mar;228(3):602-8. (PMID: 22833450)
Trends Mol Med. 2013 Jun;19(6):355-67. (PMID: 23601906)
Substance Nomenclature :
0 (GPI-Linked Proteins)
415SHH325A (Adenosine Monophosphate)
EC 3.1.3.5 (5'-Nucleotidase)
EC 3.1.3.5 (NT5E protein, human)
K72T3FS567 (Adenosine)
Entry Date(s) :
Date Created: 20140816 Date Completed: 20150511 Latest Revision: 20211021
Update Code :
20211022
PubMed Central ID :
PMC4121992
DOI :
10.1155/2014/460654
PMID :
25126561
Czasopismo naukowe
Purinergic signaling has emerged as an important player in cancer progression and is regulated by a series of nucleotidases. Among the enzyme cascade, CD73, which catelyzes AMP breakdown to adenosine, has been found to be overexpressed in many types of cancer. Various factors and mechanisms are employed to regulate expression of CD73. Accumulating studies have shown that CD73 is a key regulatory molecule of cancer cells proliferation, migration and invasion in vitro, tumor angiogenesis, and tumor immune escape in vivo. With such important roles in cancer, CD73 has become an appealing therapy target. Recent evidences in mice models demonstrated that targeted blockade of CD73 could be a favorable therapeutic approach for cancer patients in the future. In this review, we will summarize the multiple roles of CD73 in cancer development, including its clinical significance, its promotive effects on tumor growth, metastasis, and angiogenesis, and its suppressive effects on immune response, regulatory mechanisms of CD73 expression, and current situation of anti-CD73 cancer therapy.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies